Kala Pharmaceuticals Inc
$ 0.75
1.49%
07 Aug - close price
- Market Cap 14,249,600 USD
- Current Price $ 0.75
- High / Low $ 0.78 / 0.72
- Stock P/E N/A
- Book Value 0.58
- EPS -105.34
- Next Earning Report 2026-08-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.69 %
- ROE -2.39 %
- 52 Week High 1030.00
- 52 Week Low 0.59
About
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$1.50
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-15 | 2025-11-19 | 2025-08-08 | 2025-05-14 | 2025-03-31 | 2024-11-12 | 2024-08-06 | 2024-05-14 | 2024-03-29 | 2023-11-13 | 2023-08-04 | 2023-05-09 |
| Reported EPS | -0.1365 | -53.5 | -65.94 | -50.66 | -1.2316 | -96.5 | -122.27 | -4.19 | -79.07 | -150.12 | -174.05 | -6.99 |
| Estimated EPS | None | -50.5 | -102 | -127 | -2.47 | -135.5 | -229 | -2.89 | -200 | 23 | -214.5 | -4.52 |
| Surprise | 0 | -3 | 36.06 | 76.34 | 1.2384 | 39 | 106.73 | -1.3 | 120.93 | -173.12 | 40.45 | -2.47 |
| Surprise Percentage | None% | -5.9406% | 35.3529% | 60.1102% | 50.1377% | 28.7823% | 46.607% | -44.9827% | 60.465% | -752.6957% | 18.8578% | -54.646% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KALA
2026-08-05 12:40:40
KALA BIO, Inc. (KALA) is a biopharmaceutical company with a market cap of US$13.6m that has transitioned into developing an on-premises AI infrastructure platform for biotech research, the Researgency.ai platform. The company faces several risks including high share price volatility, substantial shareholder dilution, and unprofitability, with recent announcements detailing a commercial deployment of its Bionic Intelligence Research Agent (BIRA) and efforts to regain Nasdaq compliance. Despite these challenges, Kala aims to become a dual-engine growth company with its biotech pipeline and AI platform.
2026-07-23 09:09:58
This article provides details about a Form 424B5 filing for Kala Pharmaceuticals Inc. dated July 22. It includes a disclaimer about the high risks involved in trading financial instruments and cryptocurrencies, emphasizing that prices may not be real-time or accurate. The content advises potential investors to understand the risks and seek professional advice before trading.
2026-07-23 03:41:43
This article announces the filing of Form 424B5 for Kala Pharmaceuticals Inc. on July 22. It is a very brief news item, primarily serving as a placeholder for a regulatory filing notification. The article provides no further details about the content of the filing or its implications for Kala Pharmaceuticals.
2026-07-09 13:26:00
Kala Pharmaceuticals, a US-listed company, is focused on developing and commercializing innovative ophthalmic therapies, particularly for corneal and retinal conditions with unmet medical needs. The company's strategy involves improving drug penetration into ocular tissues and targeting specialty ophthalmology practices to build a portfolio with recurring prescription demand. Its business model balances clinical investment with potential revenue from marketed assets, operating within the competitive US biopharmaceutical market.
2026-07-09 11:39:59
Kala Pharmaceuticals, a US-listed company, is concentrating on developing innovative ophthalmic therapies to address unmet medical needs in eye care. Its strategy involves advancing specialty treatments, focusing on drug delivery technologies, and targeting conditions like corneal and retinal diseases. The company's business model emphasizes proprietary formulations, clinical trials, and regulatory approvals within the US market, with investor interest tied to its pipeline and regulatory milestones.
2026-07-07 16:20:00
Kala Pharmaceuticals is refocusing its strategy on targeted therapies for ocular surface diseases amidst the evolving biotech landscape. The company emphasizes advancing its pipeline with innovative drug delivery technologies for unmet needs in ophthalmology, rather than short-term market fluctuations. Its approach involves proprietary formulations to improve drug delivery to the eye and building relationships with industry stakeholders.
